Willow Biosciences vs Enbridge: Fair Value & Quality
Both stocks run through our valuation models. Here is how Willow Biosciences (CANSF) and Enbridge (ENB) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Enbridge as the less overvalued of the two: Willow Biosciences trades at $0.08 versus a fair value of $0.04 (-47%), while Enbridge trades at $51.28 versus $47.20 (-8%).
Willow Biosciences
CANSF · USD · Materials
-47%
upside to fair value
overvalued
Price$0.08
Fair Value$0.04
Quality53/100
Enbridge
ENB · USD · Energy
-8%
upside to fair value
fairly valued
Price$51.28
Fair Value$47.20
Quality39/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Willow BiosciencesEnbridge
Valuation
—P/E (TTM)26.9×
14.45×P/S (TTM)1.78×
2.47×P/B1.43×
—EV/EBITDA12.9×
—PEG5.32×
—Dividend yield6.8%
—Dividend per share$3.80
Profitability
0%Net margin10%
0%Operating margin15%
-28%Return on equity10%
-17%Return on assets3%
Growth
3349%Revenue growth (YoY)21%
389.4%Avg. growth/yr (3Y)6.9%
133.4%Avg. growth/yr (5Y)10.8%
Balance & size
0.03×Debt / equity1.15×
$67MMarket cap$123B
mixedGrowth qualityexpensive
Enbridge leads: 4 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Willow Biosciencesof which business quality 53 · market factors 2Enbridgeof which business quality 39 · market factors 61
ProfitabilityMargins and returns on capital today
0
29
Quality GrowthAre margins and returns improving?
75
49
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
16
20
Low VolatilityCalm price path (market factor)
0
86
MomentumPrice trend over the last 3–12 months (market factor)
5
49
52W MomentumDistance to the 52-week high (market factor)
0
54
Net IssuanceBuybacks instead of dilution
0
62
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Willow Biosciences
Asset-Based$0.03
1 of 1 models see the stock below the current price.
Enbridge
DCF Models$11.43
Earnings-Based$47.20
Dividend Discount$95.43
Multiples$35.83
Asset-Based$26.24
Growth DCF$4.03
Economic Profit$18.87
Growth Earnings$58.48
19 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Willow Biosciences
Bear $0.03Fair Value $0.04Bull $0.05
$0.08 = current price (white tick)
Enbridge
Bear $36.02Fair Value $47.20Bull $60.03
$51.28 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Willow Biosciences · Materials
Quality score53 · above median
Fair value upside-47% · below median
Enbridge · Energy
Quality score39 · below median
Fair value upside-8% · above median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Enbridge as the less overvalued of the two: Willow Biosciences trades at $0.08 versus a fair value of $0.04 (-47%), while Enbridge trades at $51.28 versus $47.20 (-8%).
Willow Biosciences has the higher quality score (53/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
